What SEC filings does NextCure, Inc. submit to the SEC?

NextCure, Inc. (NXTC) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about NXTC?

A Form 4 for NXTC discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from NextCure, Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for NXTC?

The 10-K is NextCure, Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all NXTC SEC filings directly on EDGAR?

You can view all historical NextCure, Inc. filings on the SEC EDGAR company page for NXTC. Each filing card on this page links directly to the original SEC document.

How often does NextCure, Inc. file with the SEC?

NextCure, Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling NXTC shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

NXTC SEC Filing News — NextCure, Inc.

Latest SEC filings for NextCure, Inc. (NXTC) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-09-25.

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; …

Sector: Healthcare Industry: Biotechnology Market Cap: $26.0M

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for NXTC currently lean bullish. Of the 20 displayed SEC filing records, 2 carry bullish classifications versus 1 bearish classifications. These labels summarize filing attributes; they are not recommendations, probabilities, or evidence of future price direction. There were 9 insider transactions (Form 4) in this period.

NXTC Filing Activity Snapshot 2026-03-05 — 2026-09-25

Insider Transactions (Form 4)

2 buys vs 1 sell

Net insider buying in this period — more purchases than sales reported.

Largest Form 144 Filing

$1.62M

ADAR1 Capital Management, LLC (10% Owner) · 2026-08-03

329,153 shares · Form 4

Insider Transactions 9 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 9 filings in this group are Form 4s for NextCure, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 9 insider filings shown, the breakdown is 6 compensation award, 2 open-market purchase and 1 open-market sale. 3 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×6: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market purchase ×2: The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.
Open-market sale ×1: The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Form 4 Open-market sale Insider Selling 2026-08-12

NXTC insider Simcere Zaiming, Inc. (Insider) sold 30,000 shares (~$184.8K)

Simcere Zaiming, Inc., listed as Insider at NextCure, Inc., reported an open-market sale of 30,000 NXTC shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	30,000	$6.16	$184.8K

Filing: Form 4 (Insider Transaction) Insider: Simcere Zaiming, Inc. (Insider) Shares: 30,000 Est. Value: $184.8K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-08-03

NXTC insider ADAR1 Capital Management, LLC (10% Owner) bought 329,153 shares (~$1.62M)

ADAR1 Capital Management, LLC, listed as 10% Owner at NextCure, Inc., reported an open-market purchase of 329,153 NXTC shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	50,000	$4.97	$248.6K
`P`	Open-market purchase	20,000	$5.00	$100.0K
`P`	Open-market purchase	20,000	$5.00	$100.0K
`P`	Open-market purchase	25,000	$4.81	$120.3K
`P`	Open-market purchase	100,000	$4.90	$490.0K
`P`	Open-market purchase	77,850	$4.96	$385.8K
`P`	Open-market purchase	3,300	$4.98	$16.4K
`P`	Open-market purchase	25,000	$4.98	$124.5K
`P`	Open-market purchase	8,003	$4.80	$38.4K

Filing: Form 4 (Insider Transaction) Insider: ADAR1 Capital Management, LLC (10% Owner) Shares: 329,153 Est. Value: $1.62M

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-07-29

NXTC insider ADAR1 Capital Management, LLC (10% Owner) bought 17,608 shares (~$87.7K)

ADAR1 Capital Management, LLC, listed as 10% Owner at NextCure, Inc., reported an open-market purchase of 17,608 NXTC shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	7,798	$5.00	$39.0K
`P`	Open-market purchase	6,400	$4.95	$31.7K
`P`	Open-market purchase	1,810	$5.00	$9.1K
`P`	Open-market purchase	1,600	$5.00	$8.0K

Filing: Form 4 (Insider Transaction) Insider: ADAR1 Capital Management, LLC (10% Owner) Shares: 17,608 Est. Value: $87.7K

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-22

NXTC insider Form 4 filed for equity award, exercise, or tax withholding

Feigal Ellen (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	2,340	—	—

Filing: Form 4 (Insider Transaction) Insider: Feigal Ellen (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-22

NXTC insider Form 4 filed for equity award, exercise, or tax withholding

Jones Elaine V (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	2,340	—	—

Filing: Form 4 (Insider Transaction) Insider: Jones Elaine V (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-22

NXTC insider Form 4 filed for equity award, exercise, or tax withholding

Borgman Anne Elizabeth (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	2,340	—	—

Filing: Form 4 (Insider Transaction) Insider: Borgman Anne Elizabeth (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-22

NXTC insider Form 4 filed for equity award, exercise, or tax withholding

Webster Stephen W (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	2,340	—	—

Filing: Form 4 (Insider Transaction) Insider: Webster Stephen W (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-22

NXTC insider Form 4 filed for equity award, exercise, or tax withholding

KABAKOFF DAVID S (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	3,510	—	—

Filing: Form 4 (Insider Transaction) Insider: KABAKOFF DAVID S (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-22

NXTC insider Form 4 filed for equity award, exercise, or tax withholding

Houston John G (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	2,340	—	—

Filing: Form 4 (Insider Transaction) Insider: Houston John G (Director)

View on SEC EDGAR → Open Filing Document →

Material Events 8 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 8 in this period for NextCure, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-09-25